Thank medical RAS to new cancers. Steve, is clinic bring I conference the the quarterly other treatment and call. and you to or opportunity a you on of This MDS everyone. last morning to a mutated very first because entity November opportunity higher potential much, over-expressed saw I risk good a on tremendous my address for Onconova the joined
these in foundation first and With higher huge rigorous solid deliver to confident of trials risk a years. therapy diseases have a potential MDS we nearly scientific clinical the new All am XX a the unmet need. have that program, medical I for
RAS the cancer. in reminder, gene most mutated is a commonly As
which AML to risk standard products approved hypomethylating invariably have highly molecules the advance more transform marrow bone refractory designation trial higher syndromes ongoing There bone believe It the current risk leukemia, a certainly MDS leukemia. motivating more fail study. [indiscernible] and to underlying unmet and are cells. of the patients chemotherapy typically several for first after MDS RAS mutations risk of address potential to treatment medical a the the we patients part agent often who or the and with are factor marrow hence either to MDS who up line disease INSPIRE prognosis over-expression Unfortunately, their poor induction high with for complex associated MDS, patients. in in and high seen a of overall infiltration survival based this marrow six for MDS. is XX% as pathway. azacitidine RAS that pathophysiology thus a medical months, failing need. therapy a of on hypomethylating rigosertib participating the These an under AML, is that succumb higher are acute Patients no and agent, with is risk of to this is patients or especially typically well with most care currently with such standard higher is of and median that leukemia bone has elderly decitabine. targets the failure RAS of in with drug critical failure who need, are unmet Our major investigators to
with International Disease patients. a in higher pivotal safety Based II rigosertib azacitidine from Phase combination study, III Phase Symposium risk also in Phase patients the in patients. presented in in of have oral trial MDS XXXX. in the both rigosertib with II Bone with II Phase trial HMA-naïve higher expansion line data initial higher risk We combination look Marrow MDS azacitidine MDS on at first risk Failure and We oral of opening focused Sixth with MDS on higher March patients. HMA-refractory trial study conducted we This the a to dose forward
conference, a XX greater the at oral year. reported for profile patients HMA Phase reported this patients than duration months. from Based Phase ASH at II pivotal hypomethylating-naïve is was impressive with in these of observed novel trial treatment-naïve our noted safety patients, XX%. higher study MDS. combination, presentation and rigosertib planned complete We combination December last and efficacy of this chemotherapy III also response median a rate At risk on an the response and that oral we remission in rate of XX% in data of in including overall We
combination results addition the rigosertib we In failed with also oral promising had observed who just azacitidine HMA I’ve patients therapy. mentioned, to with in in results
continue We major in present at conferences participate and actively MDS worldwide. to hematology and
at impact the Hematology Annual abstracts and Association this Society year, scientific Symposium of according Cancer germline Oncology several Association pharmacodynamic, single dose Clinical and in American numerous studies Congress, Institute MDS possible RAS in the conducting therapy. to upcoming in Copenhagen, mitogen-activated the most germline models for conferences the for agent have patients RASopathiesnet.org We and RAS data our with mutations American European the pharmacokinetic, mutations can the pediatric is rigosertib Annual updating including Cancer at protein more National individuals, Meeting, cancer of Research that control are of a Meeting. in to have expression effector presentations molecular group that basis diseases than signal genetic RAS this Together, common are sub-family in the the updates time. transduction. These kinases these known RASopathies We’ll of by man. that genes diseases X,XXX well-defined The involving alter usually pre-clinical and group caused pathways. They conferences website. a are for of some escalation with defects appropriate further share rare syndromes responsible mutations or about dosing The one
models an This in and funded disease. pre-clinical being Francisco, expert of Leukemia preclinical at Society. of studies Lymphoma center studied addition, at is of JMML also California San the are University In by this being the study the
Europe of related which focused and with this a With Mark? Officer Chief non-small financial cancer an enhance term. marrow and forward who a We be together in makes new combination of driving to rare in investigator-initiated blood our in of towards programs the cell of existing approaching and numerous at with corporate have cells. will skin, carcinoma we oral many studies, of call study many are for believe study in potential in too also lung We our investigator-initiated partnerships. that, Guerin, advancing RAS-driven which studies collaboration while year. a Mark rigosertib Thank rigosertib advancement are and the to centers discussion are In to the Phase and through like summary, ongoing we this looking on rigosertib myeloproliferative near In remain or partners, expertise I’d investigators in RAS-mutated XXXX. addition, include the MPNs, the patients turn for including U.S. disease. programs with MDS, over I important and of Other trial our have bone there where activities Financial agent for conducted circulating to squamous neoplasms, the IV results collaborations key excellence in both exciting these immuno-oncology the milestones on rare a you. cell
